.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Cantor Fitzgerald
Express Scripts
Harvard Business School
Medtronic
Queensland Health
Daiichi Sankyo
Federal Trade Commission
Fuji
Colorcon

Generated: November 20, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 208036

« Back to Dashboard
NDA 208036 describes E-Z-PAQUE, which is a drug marketed by Bracco and is included in one NDA. It is available from one supplier. Additional details are available on the E-Z-PAQUE profile page.

The generic ingredient in E-Z-PAQUE is barium sulfate. One supplier is listed for this compound. Additional details are available on the barium sulfate profile page.

Summary for 208036

Tradename:
3
Applicant:
1
Ingredient:
1
Patents:0
Formulation / Manufacturing:see details

Pharmacology for NDA: 208036

Mechanism of ActionX-Ray Contrast Activity

Medical Subject Heading (MeSH) Categories for 208036

Suppliers and Packaging for NDA: 208036

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
E-Z-CAT DRY
barium sulfate
FOR SUSPENSION;ORAL 208036 NDA E-Z-EM Canada Inc 32909-750 32909-750-03 24 BOTTLE, PLASTIC in 1 CARTON (32909-750-03) > 176 g in 1 BOTTLE, PLASTIC
E-Z-CAT DRY
barium sulfate
FOR SUSPENSION;ORAL 208036 NDA E-Z-EM Canada Inc 32909-764 32909-764-01 24 BOTTLE in 1 CARTON (32909-764-01) > 340 g in 1 BOTTLE

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:FOR SUSPENSION;ORALStrength98% (334GM/BOTTLE)
Approval Date:Jan 11, 2016TE:RLD:Yes

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:FOR SUSPENSION;ORALStrength96% (169GM/BOTTLE)
Approval Date:Apr 7, 2017TE:RLD:Yes

Summary for product number 003

Active Rx/OTC/Discontinued:RXDosage:FOR SUSPENSION;ORALStrength40% (9GM/POUCH)
Approval Date:Jan 3, 2017TE:RLD:Yes


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

UBS
Deloitte
Healthtrust
Express Scripts
Mallinckrodt
Covington
Julphar
QuintilesIMS
Cantor Fitzgerald
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot